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Sensitivity analyses show these results are robust. With 
average body weight, the break-even price of Peg-α-2b may 
be 7.3% higher than Peg-α-2a to have similar total costs.
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1  Introduction
Chronic hepatitis C virus (HCV) infection is a disease with 
a global prevalence rate of about 180 million individu-
als, and every year three to four million people are newly 
infected [1-3]. The impact of HCV on human health is 
evident, as 80% of acute hepatitis C cases transform into a 
chronic form and 10-20% of these cases progress to hepa-
tocellular carcinoma [3].
Currently, reliable official statistics in Ukraine are 
limited and mainly consist of data on acute HCV infection 
with jaundice and do not take into the account patients 
without jaundice and other clinically apparent manifes-
tations who comprise nearly 85% of all morbid events [4, 
5]. Ukraine is considered a country with a moderate prev-
alence of hepatitis C estimated at 1.5 to 3.5% of the popula-
tion or 700,000 to 1.61 million of people [6]. Additionally, 
HCV infection rates among high risk groups in Ukraine, 
primary drugs users, homosexual males, and female 
sex workers, reach 40 to 60%, essentially exceeding the 
average global rate [7].
In Ukraine as in most countries, if treatment is indi-
cated, the standard of HCV treatment is a combination 
therapy using either pegylated interferon α-2b (Peg -α-2b) 
or α-2a (Peg -α-2a) with ribavirin. Response to therapy is 
measured in terms of sustained virologic response (SVR), 
Abstract: Based on the pivotal trial showing no clinical-
lyrelevant differences between pegylated interferon α-2b 
(Peg-α-2b) and α-2a (Peg-α-2a)  combined with ribavirin 
for treatment of chronic hepatitis C virus (HCV) genotype 
1 infection in Ukraine, a cost-minimization analysis was 
performed using a 1 year time horizon and both a health 
care and patients’ perspective. A decision tree reflects 
treatment pathways. Drug costs were based on drug label-
ing and adjusted to the average body mass in Ukraine. 
Subgroup analysis was applied to deal with heterogene-
ity of patient’s weight causing dose changes. A break-even 
price of Peg-α-2a and Peg-α-2b (based on the average dose) 
was calculated. Univariate sensitivity analyses and prob-
abilistic sensitivity analysis were carried out to reflect 
decision uncertainty. For an average body weight, total 
medical costs per patient differ from US$9220 for Peg-α-2b 
to US$9513 for Peg-α-2a from a health care perspective, and 
from US$15,212 to US$15,696 from a patients’ perspective. 
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which is defined as undetectable HCV RNA concentrations 
6 months after completion of therapy. Successful treat-
ment of HCV depends on the virus genotype. The most 
common and least responsive to therapy are patients who 
have HCV genotype 1 (estimated 43.7% of all HCV cases or 
302,000 to 704,000 people in Ukraine) [6, 8, 9].
The proportion of subjects who achieve early virologic 
response (defined as a 2 log or greater decrease in HCV 
RNA levels at week 12) and also have an SVR is called a 
positive predictive value. A difference in the predictability 
of viral clearance between Peg -α-2b + ribavirin and Peg 
-α-2a + ribavirin may cause a cost difference in treatment 
because a lower positive predictive value may result in a 
longer duration of therapy without achieving success.
Despite a great deal of research on this topic, trans-
ferring results from previous studies conducted in US or 
Western European countries may not be possible due to 
different socio-economic systems, health care settings, 
cost parameters and their relation to different perspec-
tives, as is the case for Ukraine.
A large multicentre randomized double-blind 
direct comparative study (ClinicalTrials.gov number, 
NCT00081770) on treating patients who were infected 
with HCV genotype 1 with Peg -α-2b or Peg -α-2a was con-
ducted in US on 3070 patients, applying treatment pat-
terns similar to real-life clinical practice [10]. Treatment-
naïve patients with genotype 1 without contraindications 
were given pegylated interferon in combination with 
high-dose ribavirin (on average 1000 mg per week) for 48 
weeks [10-14]. During the treatment, patients’HCV-RNA 
was measured after 4, 12, 24, and 48 weeks, the results of 
which indicated intermediate treatment success. The rates 
of SVR and tolerability did not differ significantly between 
the two available pegylated interferons + ribavirin reg-
imens, with SVR rate of 39.8% (95% confidence interval 
[CI], 36.8 to 42.8) for standard-dose Peg -α-2b, and 40.9% 
(95% CI, 37.9 to 43.9%) for Peg -α-2a. Although no statis-
tically significant difference in efficacy between Peg-α-2a 
and Peg -α-2b was reported [10], drugs differed in the pre-
dictability of viral clearance (positive predictive value on 
week 12 was equal to 82% and 76% for Peg -α-2b + ribavirin 
and Peg -α-2a + ribavirin, respectively) and relapse rates 
that may result in differences in treatment cost.
An earlier US cost-effectiveness analysis for a hypo-
thetical cohort of 100 HCV patients with mixed genotypes 
based on the level of positive predictive value [13] showed 
no clinically relevant difference in treatment outcome 
and lower cost of treatment with Peg -α-2b + ribavirin 
compared to Peg -α-2a + ribavirin. As stated above, differ-
ences in health care systems and perspectives of analysis 
may arouse a potential difficulty for transferring these 
US-based results (adjusting the costs and/or the cost-ef-
fectiveness estimate) to other countries [15]. Moreover, 
in routine clinical practice in Ukraine, an HCV genotype 
test is performed before treatment initiation. As treatment 
standards and drug instructions recommend different 
schemes for genotype 1 versus other HCV genotypes [16, 
17], we considered that cost analysis should be also con-
ducted separately for different HCV genotypes with clini-
cal data based on a direct comparative trial.
No studies to our knowledge have been published on 
the assessment of pegylated interferons efficiency in coun-
tries belonging to the former Soviet region. Therefore, we 
aimed to study the costs of using Peg -α-2b in comparison 
to Peg -α-2a both combined with ribavirin for patients with 
HCV genotype 1 infection in the Ukrainian health care 
setting.
2  Materials and methods
For analysing the costs of using Peg -α-2b in comparison 
to Peg -α-2a both combined with ribavirin for patients with 
HCV genotype 1 infection in the Ukrainian health care 
setting, we used a decision analytic approach. Because no 
information on life-long treatment effects is available in 
the literature, a one year time horizon reflecting length of 
treatment for genotype 1 patients was defined. This rela-
tively short time horizon makes a decision tree analysis the 
appropriate method to obtain accurate cost estimations.
The structure of the decision tree was based on 
US-study protocols’ recommendations [11, 16,17]. The treat-
ment response in the model was based on the US-based 
comparative trial which assessed response at 6 months 
after the last dose of pegylated interferon. We assumed 
that no additional medical services were received after 
treatment was discontinued or completed. Our cost analy-
sis was conducted from both the health care and patients’ 
perspectives (parties which are frequent payers for treat-
ment of HCV in the Ukrainian health care setting) with 
only direct medical expenses included in the calculation. 
Although the trial [10] found no statistically significant 
difference in clinical effect (SVR), besides the cost mini-
mization (per one patient and per cohort) analysis, Cost 
per SVR achieved was calculated since a non-significant 
difference in effect may have a meaningful difference in 
costs. Break-even price of Peg-α-2a and Peg-α-2b (the point 
at which cost-effectiveness results were equal) was evalu-
ated as well.
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2.1  Clinical input data
Similar to the trial [10] in the model, virologic test proce-
dures for HCV-RNA were defined after the 4th, 12th, 24th, and 
48th week of therapy initiation. After each virological test, 
some patients discontinued treatment with Peg -α-2b + 
ribavirin or Peg -α-2a + ribavirin due to treatment failure or 
adverse effects (Figure 1). These discontinuation numbers 
were retrieved from the clinical trial report (ClinicalTrials.
gov number, NCT00081770; the report was provided by 
MSD Outcome Research), excluding those patients whose 
follow up data were missing. This resulted in a difference 
in the number of patients continuing treatment after each 
virological test (treatment week 12 and 24). According to 
the trial report, a number of patients discontinued treat-
ment between visits on 24th and 48th weeks (2.85% for Peg 
-α-2b and 5.7% for Peg -α-2a). In the model, these patients 
were assumed to be in treatment for 36 weeks on average. 
Drug dose selection was based on drug labeling; a dosage 
of the Peg -α-2b preparation was adjusted according to the 
patient’s weight, in contrast to a fixed dose of 180 mcg 
for Peg -α-2a. The analysis was conducted using the ade-
quate dose according to drug labelling (100 mcg dose for 
Peg -α-2b and 180 mcg for Peg -α-2a) and to average body 
weight in Ukraine (74 kg).
2.2  Cost input data
Cost analysis from the health care perspective included 
costs of drug treatment and costs of medical personnel. 
While costs of the pegylated interferons were determined 
from state registered prices, expenses of medical person-
nel services were calculated according to medical services 
norms in Ukraine (time per patient consultation equalled 
12 minutes and the number of working hours per week was 
33 hours for a physician and 38.5 hours for a nurse) [18].
Patients’ perspective costs were defined by out of 
pocket payments for drugs and laboratory tests (antibod-
ies to HCV, quantitative prolactin) (Table 2) Patient pay-
ments for drugs were assessed from the state registered 
prices with the distributors and trade margins established 
by the Order of the Cabinet of Ministers of Ukraine from 
24.09.2012 (Table 1). A test for antibodies to HCV (usually 
conducted once on treatment initiation) costs $13.77 
(exchange rate 1 USD = 7.99 UAH on 01.01.2014 by the 
National Bank of Ukraine) [19].
The costs related to ribavirin (weight dependent) were 
not considered in the model in both perspectives because 
due to policies of the manufacturers of both drugs, riba-
virin is provided free of charge by the companies when 
purchasing pegylated interferons. Because the reported 
adverse event profiles for both of the drugs were similar 
[10], the costs associated with adverse events were not 
included.
Figure 1: Decision tree comparing two strategies for genotype 1 HCV treatment
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2.3  Sensitivity analysis
To reflect the uncertainty inherent in the research, univar-
iate sensitivity analyses were performed using alternative 
assumptions regarding providers’ costs and diagnostics’ 
costs. To reflect decision uncertainty, probabilistic sensi-
tivity analysis (PSA) (1000 draws using Monte Carlo sim-
ulation) were carried out. In the PSA, cost of drugs and 
medical personal were varied in range ±20%, and costs 
of the laboratory analysis on quantitative prolactin were 
derived from the minimum to maximum price lists of the 
laboratories providing their services in Ukraine (Table 
2) [19].
For valuing parameters in the model from the original 
trial data, patients with missing outcomes were excluded. 
For instance, the confidence interval (CI) with 95% CI for 
the parameter “number of patients who completed 48 
week treatment” was not available, while the 95% CI for 
negative and positive 48 weeks responders was almost 
similar between both drugs compared. We assumed that 
the 95% CI for 48 weeks completers had a similar range 
to positive 48-weeks responders for both strategies (±4% 
Peg-α-2b and ±3.75% for Peg-α-2a). The number of 48-week 
completers caused changes in cohort drug costs, labora-
tory cost, and medical personal costs.
We used subgroup analysis to deal with heterogeneity 
of patient’s weight causing changes in doses of Peg-α-2b 
according to drug labelling; less than 40 kg: 50 mcg of 
Peg-α-2b; 40-64 kg: 80 mcg of Peg-α-2b; 65-75 kg: 100 mcg 
of Peg-α-2b; 75-85 kg: 120 mcg of Peg-α-2b; more than 86 
kg: 150 mcg of Peg-α-2b.
Ethical approval: The conducted research is not related 
to either human or animals use.
3  Results
The results of the cost analysis are presented in the Table 
3. Total medical costs per one patient (accounting the 
average body mass in Ukraine) varied from $9220 for Peg-
α-2b to $9513 for Peg-α-2a from a health care perspective, 
and from $15,212 for Peg-α-2b to $15,696 for Peg-α-2a from 
a patient’s perspective. The total cost for an estimated 
population of patients with HCV genotype 1 in Ukraine 
varied from a minimum of $2.780 billion (for Peg-α-2b) to 
$2.868 billion (for Peg-α-2a) and to a maximum of $6.487 
billion (for Peg-α-2b) to $6.693 billion (for Peg-α-2a) from 
a health care perspective. Using break-even point analy-
sis, it was defined that a price of Peg-α-2b should be 7.3% 
higher than Peg-α-2a to have equal/similar total costs. The 
cost per successfully treated patient, defined as having 
an SVR, was lower for Peg-α-2b in comparison to Peg-α-2a 
from patients’ perspective and almost similar between 
treatments from a health care perspective.
The results of univariate sensitivity analyses in geno-
type 1 patients are shown in Table 4. The costs of medical 
assistance and laboratory tests did not have a significant 
impact on total cost difference. For the subgroup analyses, 
the cost difference between Peg -α-2b and Peg -α-2a varied 
from 6.90% (weight less than 40 kg) to 0.56% (weight 
more than 86 kg) from a health care perspective, and from 
6.81% (weight less than 40 kg) to 0.63% (weight more than 
86 kg) from a patient’s perspective. The costs per patient 
and costs per SVR in accordance to the mode trial dose of 
Peg-α-2b [10] were slightly higher than using body mass-
based calculation for Ukraine, though a general cost dif-
ference in favour of Peg-α-2b was observed.
PSA results showed an average cost difference of 2.19 
and 2.25% from the health care and patients perspectives 
respectively (median 3.84%, std. error = 1.37% from the 
health care; median 3.80%, std. error = 1.34% from the 
patients’ perspective) in favour of Peg -α-2b + ribavirin. 
Mean SVR rates as a result of the PSA (40.08% for Peg 
-α-2b + ribavirin and 41.03% for Peg -α-2a + ribavirin) were 
similar to the deterministic data confirming the validity of 
the calculations.
Table 1: Cost of drug treatment: HCV genotype 1.
Regime Drug costs (Health 
care perspective), $*
Drug costs (Patient’s 
perspective), $**
Peg-α-2a (180 mcg) 264.02 316.82
Peg-α-2b (120mg) 277.20 332.64
Peg-α-2b (50mg) 265.00 318.00
Peg-α-2b (80mg) 268.20 321.84
Peg-α-2b (100mg) 275.90 331.08
Peg-α-2b (150mg) 283.05 339.66
* Prices as given on the website of the Ministry of Health of Ukraine 
(http://www.moz.gov.ua/ua/portal/register_prices_drugs/) on 
01.01.14
** Drugs prices with the distributors and trade margins established 
by the Order of Cabinet of Ministers of Ukraine #880 from 
24.09.2012 
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Table 2: Decision-tree model input parameters 
Parameter, measure Value in deterministic 
model 
Source Value in PSA Source
The proportion of patients 
who completed 48 week Peg 
2b, % 
47.89% [16] 43.89-51.89% ClinicalTrials.gov number, 
NCT00081770
The proportion of patients 
who completed 48 week Peg 
2a, %
55.26% [16] 51.51-59.41% ClinicalTrials.gov number, 
NCT00081770
SVR Peg-2a, % 40.90% [16] 37.90-43.90% McHutchison et al. (2009)
[10]
SVR, Peg-2b,% 39.80% [16] 36.80-42.80% McHutchison et al. (2009) 
[10]
Average monthly salary of a 
medical worker, $*
$296.00 National statistics service 
of Ukraine, 2013 [20]
$236.80-355.20 20% variation from the 
data in deterministic model 
Cost of the laboratory test on 
quantitative prolactin, $*
$84.05 [19] $47.56-$120.53 Dolkar’s initiative for Viral 
Hepatitis patients care, 
2009 [20]
* Exchange rate UAH/USD is 7.99 on 01.01.2014 by National Bank of Ukraine
Table 3: Economic outcomes per patient infected with HCV genotype 1
Regimen, weekly Health Care Perspective Patient’s perspective
Total costs, US$ Cost/SVR, US$ Total costs, US$ Cost/SVR, US$
Peg-α-2a (not weight dependent,180 
mcg) 
9513 23,202 13,969 28,539
Peg-α-2b (expected dose consumption 
in Ukraine, average 100mcg) 
9220 23,165 15,212 28,352
Peg-α-2b (mode trial dose,120mcg) 9264 23,276 15,283 28,482
Table 4: Sensitivity of cost differences to uncertainty in input values (per patient)
Parameter estimates Cost difference (Health care perspective), US$ Cost difference (Patient’s perspective), US$
Base-case result 293 360
Patients’ weight 
<40kg 657 797
>86 kg 54 74
Cost of medical assistance 
Maximum value 293 -
Minimum value 293 -
Cost of HCV laboratory test
Maximum value - 304
Minimum value - 312
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4  Discussion
The results from this cost comparison suggest that therapy 
with Peg -α-2b + ribavirin may be less costly than Peg -α-2a 
+ ribavirin for patients with genotype 1 HCV infection in 
cases in which no statistically significant difference in the 
rates of SVR achieved is assumed [10]. As the positive pre-
dictive value is higher for Peg -α-2b among patients with 
genotype 1 with no effect on clinical outcome (SVR), it 
leads to a lower number of patients receiving treatment 
when successful outcome is not possible, and so to lower 
cost per successful treatment because the probability of 
successful treatment is equal between the strategies. 
The results of the sensitivity analyses showed that input 
parameters such as cost of medical assistance and labo-
ratory tests do not affect the results of the base case anal-
ysis substantially. Because Peg -α-2b allows weight-based 
dosing, the subgroup analyses showed the economic 
advantage may be higher for patients with lower weight 
and lower for patients with higher weight than average. 
Adjustment to the patient’s body weight can lead to addi-
tional cost reductions from both patients’ and health care 
perspectives.
Due to possible price changes for pharmaceutical 
products on the Ukrainian market as a result of negoti-
ation policy of distributors and producers participating 
in state tender purchases (no reimbursement currently 
exists in Ukraine), we consider that the break-even price 
instead of the actual price should be considered to deter-
mine cost efficiency of the product in Ukraine. Price var-
iation because of negotiations is a frequent action on the 
Ukrainian state pharmaceutical market, and a similar 
strategy was announced by the Ministry of Health of 
Ukraine in relation to access to hepatitis treatment [21]. 
The higher positive predictive value of Peg -α-2b may lead 
to cost savings as long as the price of Peg -α-2b is not more 
than 7.3% higher than Peg -α-2a.
Treatment with pegylated interferon + ribavirin for 
chronic hepatitis patients is considered to be a standard 
therapy in many countries. In Ukraine, application of this 
scheme competes with interferon + ribavirin treatment 
(from 40 to 60% of the prescriptions by experts’ estimates 
[personal communication with treating physicians]). As 
final clinical outcomes of HCV treatment such as virus 
eradication and prevention of death and progression to 
cirrhosis and hepatocellular carcinoma occur over a long 
period of time and are difficult to measure, SVR can serve 
as a surrogate indicator whether the treatment goal has 
been achieved [22]. Several studies indicate the associa-
tion of SVR with improvements in liver histology, proba-
bility of developing liver decompensation, quality of life, 
and survival [23-28]. While the majority of the population 
of Ukraine cannot afford expensive drug products [29], 
patient access to treatment with pegylated interferon plus 
ribavirin is crucial in the Ukrainian health care setting.
The methods used here, a decision analysis using data 
from one pivotal trial, allowed us to derive essential clin-
ical parameters for valuing the model parameters (such 
as number of patients continuing the therapy after each 
measurement of virologic control). Another direct com-
parative trial focused on measuring SVR as an outcome of 
treatment of naïve patients with genotype 1 HCV (instead 
of mixed genotypes). These data were not included in our 
model as no significant clinical difference in the limited 
treatment groups (37 patients in each one) was reported 
[30]. Since these results are similar, we do not expect dif-
ferences in the results of economic evaluation if these 
additional data were to be incorporated to value param-
eters in the model.
While the largest comparative trial was used for clin-
ical input data, it should be noted that the previous sys-
tematic review [31] provided assessment of efficacy with 
pegylated interferon treatment for patients with a mixed 
genotype, while no genotype-specific comparison was 
conducted. Meanwhile, for treatment naïve HCV patients 
with genotype 1, there were only four studies were SVR 
was used as efficacy measure. Two of these trials, con-
ducted by Sinha et al and Yenice et al., included a limited 
number of patients, enrolling 42 and 80, respectively 
[30,32]. Two studies by Rumi et al. and Ascione et al., both 
conducted in Italy (178 patients and 181 patients with gen-
otype 1 HCV, respectively), reported the same probability 
(p=0.04) for Peg -α-2a + ribavirin to be clinically superior 
to Peg -α-2b + ribavirin [33,34]. The current cost-minimi-
zation analysis was based on the clinical data from the 
largest trial available which showed no statistically sig-
nificant difference between treatment arms. The weighted 
pooled data from the three trials has shown almost similar 
SVR rates for genotype 1 patients (41.5% for Peg -α-2a + 
ribavirin and 40.2 % for Peg -α-2b + ribavirin) to the data 
used in the current study [10,33,34]. While this adjust-
ment has no impact on the results of the current cost-min-
imization study, the cost for one SVR reached remained 
equal for both drugs. Several economic studies on treat-
ment of naïve patients with chronic HCV infection have 
been published in different countries [12-14,35]. The most 
recent study on pegylated interferons was conducted for 
the US [13], applying similar methodology as our study, 
defining the cost-efficacy of Peg -α-2b + ribavirin scheme 
for patients with HCV (genotypes 1,2,3). Though the aim 
of the study was similar, the perspective of the US-study 
was one of a managed care organization. Thus, using the 
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transferability criteria for cost-effectiveness estimates as 
stated by the ISPOR taskforce on transferability [15], it 
may not be applicable for Ukraine, where major treatment 
costs for HCV treatment are partially covered by patients’ 
payments and partially by government through state pur-
chases. Despite the difference in perspectives, Malone et 
al. reached the similar conclusion, stating that treating 
with Peg -α-2b + ribavirin provides cost savings in com-
parison to Peg -α-2a + ribavirin because fewer patients are 
treated beyond 12 weeks when achieving SVR is unlikely 
[13]. The indicated study suggested that although both Peg 
-α-2a and Peg -α-2b have demonstrated similar SVR overall, 
for genotype 1, there is a significant difference in early 
virologic response rates. Thus, using Peg -α-2a + ribavirin 
for genotype 1 patients may cause more treatments’ 
consumption for the patients’ cohort without additional 
health benefit over those treated with Peg -α-2b.
A number of other economic studies compared treat-
ment with interferons and pegylated interferons for geno-
type 1 HCV treatment-naïve patients [12,14,35], confirming 
cost-effectiveness of the latter one. A study in Spain, con-
ducted by Buti et al. , also defined treatment with Peg -α-2b 
+ ribavirin as the optimal strategy which includes adjust-
ment to the patient’s body weight for 48 weeks and good 
therapeutic compliance [12]. Siebert et al. concluded that 
Peg -α-2b + ribavirin could reduce the incidence of liver 
complications, prolong life, improve quality of life, and be 
cost effective for the initial treatment of HCV in patients 
in Germany[35]. Sullivan et al. evaluated cost-effective-
ness of Peg -α-2a + ribavirin versus traditional interferon, 
coming to the similar conclusion on efficiency pegylated 
interferons in patients in the US [14].
In our analysis comparing two pegylated interferons, 
we observed similar results with the study of Malone et 
al. , though due to differences in sources of clinical out-
comes (SVR rates), cost components, and prices, the total 
costs were different [11]. Thus, the results from our study 
may help to assess costs for HCV genotype 1 treatment 
in Ukraine and may be more easily transferable to other 
former Soviet countries.
This analysis suggests that use of Peg -α-2b + ribavi-
rin may be preferred to Peg -α-2a + ribavirin in treatment 
of genotype 1 HCV infected patients due to lower costs 
associated with treatment, given the earlier finding of 
comparable clinical efficacy. Use of Peg -α-2b + ribavirin 
in comparison to Peg-α-2a + ribavirin could lead to a cost 
reduction of $88 to $206 per patient if the treatment for all 
the cohort of genotype 1 HCV patients is provided. Price 
of Peg -α-2a would have to be lower to achieve similar effi-
ciency to Peg -α-2b.
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